101 related articles for article (PubMed ID: 8490909)
1. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Wilkinson MJ; Frye JW; Small EJ; Venook AP; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1993 Jun; 71(11):3601-4. PubMed ID: 8490909
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
3. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Hrushesky WJ; von Roemeling R; Lanning RM; Rabatin JT
J Clin Oncol; 1990 Sep; 8(9):1504-13. PubMed ID: 2144018
[TBL] [Abstract][Full Text] [Related]
4. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
Conroy T; Geoffrois L; Guillemin F; Luporsi E; Krakowski I; Spaëth D; Frasie V; Volff D
Cancer; 1993 Oct; 72(7):2190-7. PubMed ID: 8374877
[TBL] [Abstract][Full Text] [Related]
5. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Reese DM; Corry M; Small EJ
Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
[TBL] [Abstract][Full Text] [Related]
7. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
von Roemeling R; Hrushesky WJ
J Clin Oncol; 1989 Nov; 7(11):1710-9. PubMed ID: 2530318
[TBL] [Abstract][Full Text] [Related]
8. Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
Falcone A; Cianci C; Ricci S; Brunetti I; Bertuccelli M; Conte PF
Cancer; 1993 Jul; 72(2):564-8. PubMed ID: 8319188
[TBL] [Abstract][Full Text] [Related]
9. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
Soori GS; Schulof RS; Stark JJ; Wiemann MC; Honeycutt PJ; Church CK; DePriest CB
Cancer Invest; 1999; 17(6):379-84. PubMed ID: 10434947
[TBL] [Abstract][Full Text] [Related]
10. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma.
Dexeus FH; Logothetis CJ; Sella A; Amato R; Kilbourn R; Ogden S; Striegel A; Kwan J; Newman RA
J Urol; 1991 Sep; 146(3):709-13. PubMed ID: 1831513
[TBL] [Abstract][Full Text] [Related]
11. Circadian-based infusional FUDR therapy.
Lanning RM; von Roemeling R; Hrushesky WJ
Oncol Nurs Forum; 1990; 17(1):49-56. PubMed ID: 2137216
[TBL] [Abstract][Full Text] [Related]
12. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
Hrushesky WJ; Von Roemeling R; Fraley EE; Rabatin JT
Semin Surg Oncol; 1988; 4(2):110-5. PubMed ID: 2969133
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy].
Del Nero A; Mandressi A; Longo G; Cogni M; Mangiarotti B; Buzzetti V; Russo R
Arch Ital Urol Nefrol Androl; 1991 Jun; 63(2):249-51. PubMed ID: 1830673
[TBL] [Abstract][Full Text] [Related]
14. Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump.
Damascelli B; Marchianò A; Spreafico C; Lutman R; Salvetti M; Bonalumi MG; Mauri M; Garbagnati F; Del Nero A; Comeri G
Cancer; 1990 Jul; 66(2):237-41. PubMed ID: 2142443
[TBL] [Abstract][Full Text] [Related]
15. Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Garufi C; Lévi F; Giunta S; Aschelter A; Pace R; Nisticò C; Terzoli E
J Infus Chemother; 1995; 5(3 Suppl 1):134-7. PubMed ID: 8528973
[TBL] [Abstract][Full Text] [Related]
16. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion.
von Roemeling R; Rabatin JT; Fraley EE; Hrushesky WJ
J Urol; 1988 Feb; 139(2):259-62. PubMed ID: 2963142
[TBL] [Abstract][Full Text] [Related]
17. Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma.
Damascelli B; Marchianò A; Frigerio LF; Salvetti M; Spreafico C; Garbagnati F; Zanoni F; Radice F
Cancer; 1991 Sep; 68(5):995-8. PubMed ID: 1833043
[TBL] [Abstract][Full Text] [Related]
18. Continuous non chronomodulated infusion of floxuridine in metastatic renal cell carcinoma (MRCC): report of 17 cases.
Baiocchi C; Landonio G; Cacioppo C; Calgaro M; Cattaneo D; Ferrari M; Majno M
Tumori; 1996; 82(3):225-7. PubMed ID: 8693598
[TBL] [Abstract][Full Text] [Related]
19. Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
Bjarnason GA; Doyle N; Sone M; Beattie K; Elia J; Owens B
J Infus Chemother; 1995; 5(2):82-8. PubMed ID: 8521240
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer.
Rajagopalan K; Peereboom D; Budd GT; Olencki T; Murthy S; Elson P; McLain D; Bukowski R
Invest New Drugs; 1998-1999; 16(3):255-8. PubMed ID: 10360605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
